AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18281670 — intervention group
Group type: COMPARATOR
Intervention: physician's choice (PC) of treatment (dacarbazine, temozolomide, interleukin-2, or complete tumor resection)
Number of subjects: 322
Study 15472642 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual strategy supplemented by resting myocardial perfusion imaging (MPI) using SPECT technetium 99m sestamibi (n = 153)
Number of subjects: 341
Study 15472642 — intervention group
Group type: COMPARATOR
Intervention: Usual strategy (n = 188)
Number of subjects: 341
Study 15472642 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual strategy supplemented by resting MPI (n = 153)
Number of subjects: 341
Study 11337242 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral head (LH) of the hamstring muscles during maximum isometric contraction at 45 degrees of knee flexion
Number of subjects: 42
Study 11337242 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral head (LH) of the hamstring muscles during submaximal isometric contractions
Number of subjects: 42
Study 11337242 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial head (MH) of the hamstring muscles during submaximal isometric contractions
Number of subjects: 42
Study 9215817 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 40 mg four times daily
Number of subjects: 288
Study 9215817 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) 250 mg four times daily with hydrocortisone (HC) 40 mg daily
Number of subjects: 288
Study 9215817 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MA plus AG at the same dosages
Number of subjects: 288
Study 7955237 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment alone
Number of subjects: 468
Study 7955237 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 468
Study 2447997 — intervention group
Group type: EXPERIMENTAL
Intervention: goserelin 3.6 mg depot (Zoladex)
Number of subjects: 139
Study 2447997 — intervention group
Group type: COMPARATOR
Intervention: stilboestrol 3 mg/day
Number of subjects: 139
Study 29965952 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant education (less than 1 hour)
Number of subjects: 1294
Study 29965952 — intervention group
Group type: COMPARATOR
Intervention: Transplant education (1 hour or longer)
Number of subjects: 1294
Study 29965952 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking to doctors/medical staff
Number of subjects: 1294
Study 29965952 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading brochures
Number of subjects: 1294
Study 29965952 — intervention group
Group type: EXPERIMENTAL
Intervention: Browsing the internet
Number of subjects: 1294
Study 29965952 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching videos
Number of subjects: 1294
Study 30145929 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of tafamidis
Number of subjects: 441
Study 30145929 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of tafamidis
Number of subjects: 441
Study 30145929 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis (both dosages)
Number of subjects: 441
Study 30145929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 27318021 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil administered via inhalation using an ultrasonic nebulizer
Number of subjects: 12
Study 27318021 — intervention group
Group type: COMPARATOR
Intervention: Vardenafil 10-mg oral tablet
Number of subjects: 12
Study 24504819 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 120
Study 24504819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 22891807 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive version of an injection risk intervention and sexual risk intervention (single 60-minute session)
Number of subjects: 584
Study 22891807 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic version of an injection risk intervention and sexual risk intervention (single 60-minute session)
Number of subjects: 584
Study 20675363 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking characters
Number of subjects: 60
Study 20675363 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking characters
Number of subjects: 60
Study 17617790 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 19
Study 17617790 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (CI)
Number of subjects: 19
Study 15894537 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (10-week single-leg knee-extension program)
Number of subjects: 67
Study 11240954 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus (FK506)
Number of subjects: 10
Study 9248782 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (1 g, Clamoxyl dispersible tablet)
Number of subjects: 20
Study 8497019 — intervention group
Group type: EXPERIMENTAL
Intervention: Light group (lifted less weight than they believed)
Number of subjects: 24
Study 8497019 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy group (lifted more weight than they believed)
Number of subjects: 24
Study 8497019 — intervention group
Group type: COMPARATOR
Intervention: Control group (no manipulation)
Number of subjects: 24
Study 3826206 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptives
Number of subjects: 12
Study 31409749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole eye drops (3.75 mg/m2)
Number of subjects: 100
Study 31409749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31409749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole eye drops
Number of subjects: 100
Study 30102656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 449
Study 30102656 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine (NVP)
Number of subjects: 449
Study 28678855 — intervention group
Group type: EXPERIMENTAL
Intervention: PowerPoint presentations
Number of subjects: 0
Study 28678855 — intervention group
Group type: EXPERIMENTAL
Intervention: Prezi presentations
Number of subjects: 0
Study 28678855 — intervention group
Group type: COMPARATOR
Intervention: Oral presentations
Number of subjects: 0
Study 26152472 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation Plus (PAV+)
Number of subjects: 160
Study 26152472 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 160
Study 26152472 — intervention group
Group type: COMPARATOR
Intervention: T-Tube Ventilation
Number of subjects: 160
Study 23715579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 183
Study 23715579 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 183
Study 21232119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin B12 (1000 μg daily, N = 26)
Number of subjects: 50
Study 21232119 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 24)
Number of subjects: 50
Study 18633597 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal invasive surgery (MIS)
Number of subjects: 90
Study 18633597 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer assisted surgery with minimal invasive approach (CAS-MIS)
Number of subjects: 90
Study 18633597 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 90
Study 18633597 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (MIS, CAS-MIS, Conventional)
Number of subjects: 90
Study 16866673 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment scales (verbal, horizontal visual, and faces pain scales)
Number of subjects: 129
Study 16866673 — intervention group
Group type: COMPARATOR
Intervention: Observational rating scale
Number of subjects: 129
Study 12562865 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (4 g/d of ethyl esters of EPA and DHA)
Number of subjects: 33
Study 10704612 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercholesterolemic patients (HC)
Number of subjects: 56
Study 10704612 — intervention group
Group type: COMPARATOR
Intervention: O(2)(‐)‐generating mixture xanthine oxidase/hypoxanthine
Number of subjects: 56
Study 9739907 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA 5% cream
Number of subjects: 63
Study 9739907 — intervention group
Group type: COMPARATOR
Intervention: Xylocaïne 1% infiltration
Number of subjects: 63
Study 7886548 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange transfusion therapy (10-15 units of blood)
Number of subjects: 9
Study 7886548 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange transfusion therapy
Number of subjects: 9
Study 7886548 — intervention group
Group type: COMPARATOR
Intervention: Matched non-exchanged patients
Number of subjects: 9
Study 29578385 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted 20-m sprints
Number of subjects: 37
Study 29578385 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted 20-m sprints
Number of subjects: 37
Study 29578385 — intervention group
Group type: COMPARATOR
Intervention: Unloaded 20-m sprints
Number of subjects: 37
Study 30024796 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing tables + Point-of-Decision Prompts (PODPs)
Number of subjects: 14
Study 30024796 — intervention group
Group type: COMPARATOR
Intervention: Point-of-Decision Prompts (PODPs) only
Number of subjects: 14
Study 27923980 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 55
Study 27923980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking
Number of subjects: 55
Study 27923980 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 24637568 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 fatty-acid consumption (MorDHA capsules: 435 mg of docosahexaenoic acid and 65 mg of eicosapentaenoic acid) for 14 months
Number of subjects: 104
Study 24637568 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules for 14 months
Number of subjects: 104
Study 22263927 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-constructed risk scenario
Number of subjects: 0
Study 22263927 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated risk scenario
Number of subjects: 0
Study 22263927 — intervention group
Group type: COMPARATOR
Intervention: Non-message condition
Number of subjects: 0
Study 20052455 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (36 supervised 1-hour sessions on a cycle ergometer over 12 weeks)
Number of subjects: 100
Study 20052455 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 100
Study 18331138 — intervention group
Group type: EXPERIMENTAL
Intervention: High alcohol risk group
Number of subjects: 36
Study 18331138 — intervention group
Group type: COMPARATOR
Intervention: Normative group
Number of subjects: 36
Study 16254727 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 600 mg/day for 1 day
Number of subjects: 236
Study 16254727 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 300 mg/day for 3 days
Number of subjects: 236
Study 16254727 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 600 mg for 1 day
Number of subjects: 236
Study 12354980 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous self-expanding metal stent
Number of subjects: 54
Study 12354980 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic polyethylene endoprosthesis
Number of subjects: 54
Study 10348224 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil (1,000 mg and 400 mg, orally at 24-hr intervals for three doses)
Number of subjects: 158
Study 8954301 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic cerebral infarction (ACI)
Number of subjects: 383
Study 8954301 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic cerebral infarction (SCI)
Number of subjects: 383
Study 8954301 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger infarctions
Number of subjects: 383
Study 8954301 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarctions in the lateral middle cerebral artery (MCA) territory
Number of subjects: 383
Study 8954301 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarctions in the medial MCA territory
Number of subjects: 383
Study 1748256 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 41
Study 6293718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime administered 30 to 90 minutes preoperatively, every 60 to 90 minutes during surgery, and immediately postoperatively.
Number of subjects: 116
Study 6293718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime or cefazolin administered according to the same regimen as the first group, plus every eight hours for 24 hours postoperatively.
Number of subjects: 116
Study 6293718 — intervention group
Group type: COMPARATOR
Intervention: Placebo (from an earlier study).
Number of subjects: 116
Study 31831051 — intervention group
Group type: EXPERIMENTAL
Intervention: YH0618 granule (6 g twice a day, 6 days a week, mixed with 300 ml warm water from the first to the fourth chemotherapy cycle)
Number of subjects: 0
Study 31831051 — intervention group
Group type: COMPARATOR
Intervention: Placebo granule (same dosage and administration as YH0618)
Number of subjects: 0
Study 31831051 — intervention group
Group type: EXPERIMENTAL
Intervention: YH0618 granule
Number of subjects: 0
Study 31831051 — intervention group
Group type: COMPARATOR
Intervention: Placebo granule
Number of subjects: 0
Study 28317624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-Assisted Colonoscopy (CAC)
Number of subjects: 440
Study 28317624 — intervention group
Group type: COMPARATOR
Intervention: Standard Colonoscopy (SC)
Number of subjects: 440
Study 25335642 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest-worn sleep position trainer (SPT)
Number of subjects: 20
Study 25335642 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 20
Study 25335642 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SPT + MAD
Number of subjects: 20
Study 24300821 — intervention group
Group type: EXPERIMENTAL
Intervention: infibeta (Russian Β-interferon-1b biosimilar)
Number of subjects: 123
Study 20824664 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO diet
Number of subjects: 59
Study 20824664 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acid diet
Number of subjects: 59
Study 20824664 — intervention group
Group type: COMPARATOR
Intervention: MUFA diet
Number of subjects: 59
Study 19415347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measures of abdominal muscle activation
Number of subjects: 35
Study 17223805 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 4 mg.kg‐1 combined with suxamethonium 1 mg.kg‐1 (group S)
Number of subjects: 60
Study 17223805 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 4 mg.kg‐1 combined with remifentanil 1.25 microg.kg‐1 (group R)
Number of subjects: 60
Study 17223805 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium (group S)
Number of subjects: 60
Study 17223805 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (group R)
Number of subjects: 60
Study 15189395 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast, a leukotriene receptor antagonist, used in real-world management of asthma
Number of subjects: 400
Study 11436940 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2% b.i.d. for 2 weeks
Number of subjects: 12
Study 11436940 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d. for 2 weeks
Number of subjects: 12
Study 11436940 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 12
Study 9744711 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled clinical trial
Number of subjects: 0
Study 9744711 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary systemic therapy
Number of subjects: 0
Study 9744711 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evaluation of response to treatment
Number of subjects: 0
Study 9744711 — intervention group
Group type: COMPARATOR
Intervention: Randomization
Number of subjects: 0
Study 7831656 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal of warfarin (group A)
Number of subjects: 32
Study 7831656 — intervention group
Group type: COMPARATOR
Intervention: Gradual withdrawal of warfarin (group B)
Number of subjects: 32
Study 7831656 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 32
Study 7831656 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (abrupt withdrawal)
Number of subjects: 32
Study 3149240 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 1 mg i.v.
Number of subjects: 20
Study 3149240 — intervention group
Group type: COMPARATOR
Intervention: Placebo i.v.
Number of subjects: 20
Study 29630032 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone 4 mg (1 mL) with 30 mL ropivacaine 0.375%
Number of subjects: 100
Study 29630032 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexamethasone 10 mg (2.5 mL) with 30 mL ropivacaine 0.375%
Number of subjects: 100
Study 28774950 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose aerobic exercise training (33.6 kJ·kg‐1 body weight weekly)
Number of subjects: 72
Study 28774950 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose aerobic exercise training (58.8 kJ·kg‐1 body weight weekly)
Number of subjects: 72
Study 28774950 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 72
Study 26491826 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 50
Study 26491826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23929578 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical appraisal exercises (CA)
Number of subjects: 42
Study 21677633 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning using an automated thigh tourniquet (three 5-min intervals of ischemia separated by 5-min intervals of reperfusion)
Number of subjects: 120
Study 21677633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 18270716 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body magnetic resonance angiography (WBMRA) with 40 ml gadodiamide
Number of subjects: 306
Study 18270716 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional cardiovascular risk factors (included in FRS)
Number of subjects: 306
Study 16563559 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine/Cisplatin (VC regimen) followed by Docetaxel/Gemcitabine (DG regimen)
Number of subjects: 59
Study 14531480 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 691
Study 14531480 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 691
Study 14531480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study 11299593 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (fed by nasogastric jejunal tube Survimed OPD, 30 kcal/kg)
Number of subjects: 181
Study 11299593 — intervention group
Group type: EXPERIMENTAL
Intervention: Early jejunal feeding combined with imipenem prophylaxis (Tienam, 2 x 500 mg i.v.)
Number of subjects: 181
Study 11299593 — intervention group
Group type: COMPARATOR
Intervention: Conventional parenteral nutrition (Rindex 10, Infusamin S, Intralipid 10%: 30 kcal/kg)
Number of subjects: 181
Study 8768914 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (three times per day)
Number of subjects: 18
Study 8768914 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 18
Study 2000752 — intervention group
Group type: EXPERIMENTAL
Intervention: High osmolar contrast media (diatrizoate, Renografin-76)
Number of subjects: 60
Study 2000752 — intervention group
Group type: COMPARATOR
Intervention: Low osmolar contrast media (ioxaglate, Hexabrix)
Number of subjects: 60
Study 6391131 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous verapamil, 5 to 10 mg/hour for 2 days
Number of subjects: 29
Study 6391131 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 patients with no specific treatment)
Number of subjects: 29
Study 29913230 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory conditions
Number of subjects: 32
Study 29913230 — intervention group
Group type: EXPERIMENTAL
Intervention: Steel Cut oatmeal breakfast
Number of subjects: 32
Study 27090574 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin administration
Number of subjects: 0
Study 27090574 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of heparin
Number of subjects: 0
Study 24740438 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced behavioral parent training (STEPP program)
Number of subjects: 80
Study 24740438 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional behavioral parent training (BPT)
Number of subjects: 80
Study 24740438 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 80
Study 24370033 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib combined with bisphosphonates (A group)
Number of subjects: 43
Study 24370033 — intervention group
Group type: COMPARATOR
Intervention: Bisphosphonates combined with traditional chemotherapy (B group)
Number of subjects: 43
Study 21358082 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan mouthwash (0.03% W/V)
Number of subjects: 24
Study 21358082 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate mouth rinse (control group)
Number of subjects: 24
Study 21358082 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan mouthwash
Number of subjects: 24
Study 17522615 — intervention group
Group type: EXPERIMENTAL
Intervention: spaghetti+2*DF
Number of subjects: 20
Study 17522615 — intervention group
Group type: COMPARATOR
Intervention: barley porridge
Number of subjects: 20
Study 15964703 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicopass 1.5 mg nicotine lozenge
Number of subjects: 24
Study 15964703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12505931 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen with 80% oxygen, balance nitrogen (Group B)
Number of subjects: 100